학술논문
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
Document Type
Article
Author
Diefenbach, Catherine S ; Hong, Fangxin; Ambinder, Richard F; Cohen, Jonathon B; Robertson, Michael J; David, Kevin A; Advani, Ranjana H; Fenske, Timothy S; Barta, Stefan K; Palmisiano, Neil D; Svoboda, Jakub; Morgan, David S; Karmali, Reem; Sharon, Elad; Streicher, Howard; Kahl, Brad S; Ansell, Stephen M
Source
In The Lancet Haematology September 2020 7(9):e660-e670
Subject
Language
ISSN
2352-3026